

Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?

The catastrophic outbreak of acute respiratory distress syndrome induced by SARS-CoV-2 (the coronavirus disease 2019, COVID-19) has strongly confirmed the important role of systemic hyperinflammation, independently of the trigger, as a major cause of death.¹ In fact, accumulating evidence suggests that a subgroup of patients with severe COVID-19 is burdened by a cytokine storm syndrome, an overwhelming systemic inflammation with a massive release of pro-inflammatory cytokines. As reported in 150 patients in Wuhan, China, a subset of patients with COVID-19 are characterised by raised levels of ferritin, which identified those patients at higher risk of poor outcome (1297.6 ng/mL in non-survivors




Figure 1 Inflammatory loop induced by high levels of ferritin. SARS-CoV-2 RNAs act as pathogen-associated molecular patterns and sense toll-like receptors, triggering downstream cascades in cells of innate immune system resulting in the production of pro-inflammatory mediators, which induce the production of ferritin. Once endocytosed, independently of its iron content, ferritin stimulates pro-inflammatory pathways, which ultimately culminates in activation of NF- κ B, thus enhancing the expression of pro-inflammatory mediators, including IL-1 β , IL-6 and IFN- γ . Although not all the receptors are simultaneously required for endocytosis of ferritin, the figure shows that all of the receptors have been found in the endosome since the binding of ferritin to different receptors is dependent on the FeH:FeL ratio. CXCR4, C-X-C chemokine receptor type 4; FeH, heavy ferritin subunit; FeL, light ferritin subunit; IL, interleukin; NF- κ B, nuclear factor- κ B; Scara5, scavenger receptor class A member 5; Tfr1, transferrin receptor protein 1; TIM, T-cell immunoglobulin and mucin domain.

compared with 614.0 ng/mL in survivors).¹ Although the amplitude of ferritin elevation is not comparable, this finding may resemble what is observed in diseases included under the umbrella of the hyperferritinaemic syndrome.² This syndrome includes macrophage activation syndrome (MAS), systemic juvenile idiopathic arthritis, adult-onset Still's disease (AOSD) and catastrophic anti-phospholipid syndrome, which are burdened by severe clinical picture and high mortality rate.² Ferritin, the common denominator of all these diseases, is an iron storage protein comprising 24 subunits of two types, heavy (FeH) and light (FeL) subunits, differently expressed in tissues.² After specific injuries, pro-inflammatory cytokines activate the liver to produce several defence proteins, such as pentraxins (ie, C reactive protein) and ferritin, multifunctional proteins at the crossroads of immunity and inflammation. Ferritin transcription responds to interleukin (IL)-1 β , IL-6 and molecules of interferon (IFN)- γ signature, which upregulate the ferritin gene transcription through the increased binding of nuclear factor- κ B (NF- κ B) to FER2 upstream of the iron responsive element and coding region.² Furthermore, during inflammation, other sources of ferritin include both secretion by macrophages and release from damaged cells. Interestingly, ferritin may actively play a pathogenic role in enhancing the inflammatory burden in the context of a pro-inflammatory milieu, characterised by high levels of IL-1 β and IL-6 (figure 1). Once endocytosed, after binding to different receptors according to the FeH:FeL ratio, independently of its iron content, ferritin stimulates pro-inflammatory pathways, which ultimately culminates in activation of NF- κ B, resulting in the increased expression of pro-inflammatory mediators, as shown on the hepatic stellate cells.³ Intriguingly, in inflammatory infiltrate of AOSD and MAS, FeH and FeH+/IL-12+ pro-inflammatory macrophages are hyper-represented, suggesting that the pro-inflammatory properties of ferritin are mainly related to FeH.⁴ The latter is released following inflammatory stimuli and binds a specific receptor on immune cells.² Furthermore, in an experimental model of sepsis, the deletion of FeH leads to a blunted activation of NF- κ B, with a consequent reduction of pro-inflammatory cytokines, including IL-1 β , IL-6, IL-12 and IFN- γ , and improving survival.⁵ It has been shown that SARS-CoV-2 RNAs, acting as pathogen-associated molecular patterns and sensing toll-like receptors, trigger downstream cascades, which activate NF- κ B, resulting in the production of pro-inflammatory mediators.⁶ In this setting, ferritin may further and repeatedly stimulate these signalling pathways, acting as enhancer of the inflammatory process in more severe COVID-19. Thus, a vicious loop is induced by ferritin and pro-inflammatory cytokines, including IL-1 β , IL-6 and IFN- γ , activating NF- κ B and contributing to the development of a cytokine storm syndrome. Finally, the inhibition of these cytokines leads to a reduction of ferritin levels, as reported in other inflammatory diseases burdened by a cytokine storm syndrome.²

In conclusion, SARS-CoV-2 and consequent COVID-19 are a new great challenge for the health systems worldwide, needing a multidisciplinary approach and a large body of knowledge. Severe COVID-19 displays many common aspects with the other disorders included in the hyperferritinaemic syndrome, and ferritin could enhance the inflammatory burden, thus contributing to a vicious pro-inflammatory loop.

Piero Ruscitti,¹ Onorina Berardicurti,¹ Antonio Barile,² Paola Cipriani,¹ Yehuda Shoenfeld,^{3,4,5} Annamaria Iagnocco,⁶ Roberto Giacomelli,¹

¹Division of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Abruzzo, Italy

²Diagnostic and Interventional Radiology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

³Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel HaShomer, Israel

⁴Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

⁵Laboratory of the Mosaics of Autoimmunity, Saint Petersburg State University, Russia

⁶Academic Rheumatology Centre, Università degli Studi di Torino, Turin, Italy

Correspondence to Professor Annamaria Iagnocco, Scienze Cliniche e Biologiche, University of Turin, Torino 10124, Piemonte, Italy; annamaria.iagnocco1@gmail.com

Handling editor Josef S Smolen

Contributors All the authors meet all criteria for authorship in the ICMJE Recommendations since all authors made substantial contributions to the conception or design of the work, the acquisition and interpretation of data. All authors contributed to the critical review and revision of the manuscript and approved the final version. All the authors agreed to be accountable for all aspects of the work.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Ruscitti P, Berardicurti O, Barile A, *et al.* *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-217618

Received 15 April 2020

Revised 11 May 2020

Accepted 12 May 2020

Ann Rheum Dis 2020;**0**:1–2. doi:10.1136/annrheumdis-2020-217618

ORCID iDs

Onorina Berardicurti <http://orcid.org/0000-0002-2808-1581>

Roberto Giacomelli <http://orcid.org/0000-0003-0670-9638>

REFERENCES

- 1 Mehta P, McAuley DF, Brown M, *et al.* COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020;395:1033–4.
- 2 Rosário C, Zandman-Goddard G, Meyron-Holtz EG, *et al.* The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. *BMC Med* 2013;11:185.
- 3 Ruddell RG, Hoang-Le D, Barwood JM, *et al.* Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. *Hepatology* 2009;49:887–900.
- 4 Ruscitti P, Cipriani P, Di Benedetto P, *et al.* H-Ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. *Clin Exp Immunol* 2018;191:220–8.
- 5 Zaijyou A, Black LM, McCullough KR, *et al.* Ferritin light chain confers protection against sepsis-induced inflammation and organ injury. *Front Immunol* 2019;10:131.
- 6 Guo Y-R, Cao Q-D, Hong Z-S, *et al.* The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. *Mil Med Res* 2020;7:11.